Anisomycin

Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system[1]. Anisomycin is a JNK activator, which increases phospho-JNK[2][3]. Anisomycin is a bacterial antibiotic[4].

Product Specifications

CAS Number

[22862-76-6]

Product Name Alternative

Flagecidin; Wuningmeisu C

UNSPSC

12352005

Hazard Statement

H301

Target

Antibiotic; Apoptosis; Bacterial; DNA/RNA Synthesis; JNK; Parasite

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/Anisomycin.html

Concentration

10mM

Purity

99.82

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 4 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O[C@@H]1[C@@H](OC(C)=O)[C@@H](CC2=CC=C(OC)C=C2)NC1

Molecular Formula

C14H19NO4

Molecular Weight

265.31

Precautions

H301

References & Citations

[1]Lu Z, et al. Colistin-induced autophagy and apoptosis involves the JNK-Bcl2-Bax signaling pathway and JNK-p53-ROS positive feedback loop in PC-12 cells.|[2]Zhengle Tang, et al. In vivo toxicological evaluation of Anisomycin. Toxicol Lett. 2012 Jan 5;208 (1) :1-11.|[3]Gao X, et al. Transcriptional regulation of stress kinase JNK2 in pro-arrhythmic CaMKIIδ expression in the aged atrium. Cardiovasc Res. 2018 Apr 1;114 (5) :737-746.|[4]Synthesis Marina Macías-Silva, et al. Anisomycin is a Multifunctional Drug: More than Just a Tool to Inhibit Protein. Current Chemical Biology, 2010, 4, 124-132.